Insights into von Willebrand factor proteolysis: clinical implications
Open Access
- 27 April 2006
- journal article
- review article
- Published by Wiley in British Journal of Haematology
- Vol. 133 (5) , 457-467
- https://doi.org/10.1111/j.1365-2141.2006.06096.x
Abstract
The proteolysis of von Willebrand factor (VWF) by the recently discovered metalloprotease ADAMTS13 (a disintegrin and metalloprotease with thrombospondin repeats), is a normal processing step in VWF biochemistry. Emerging data indicate that this step may be influenced by a variety of factors, some of which favour increased proteolysis and some of which compromise proteolysis. The former may predispose to bleeding, whilst the latter appears to be the underlying mechanism for thrombotic thrombocytopenic purpura (TTP). The new insights support the concept of "risk" in bleeding, particularly in the case of type 1 von Willebrand disease (VWD), in much the same way that risk is considered in venous thrombosis. This review presents relevant current knowledge of VWF proteolysis by ADAMTS13, and a novel model of how this may be implicated in type 1 VWD is proposed, based on events at the vessel wall at a time of haemostatic challenge.Keywords
This publication has 72 references indexed in Scilit:
- Bombay phenotype is associated with reduced plasma-VWF levels and an increased susceptibility to ADAMTS13 proteolysisBlood, 2005
- The Y/C1584 mutation of von Willebrand factor in type 2M von Willebrand disease: frequency and clearance of von Willebrand factorBritish Journal of Haematology, 2005
- Theoretical structural explanation for Group I and Group II, type 2A von Willebrand disease mutationsJournal of Thrombosis and Haemostasis, 2005
- The prevalence of the cysteine1584 variant of von Willebrand factor is increased in type 1 von Willebrand disease: co‐segregation with increased susceptibility to ADAMTS13 proteolysis but not clinical phenotypeBritish Journal of Haematology, 2005
- Increased susceptibility of von Willebrand factor to proteolysis by ADAMTS13: should the multimer profile be normal or type 2A?Blood, 2004
- ACTIVATED PROTEIN C RESISTANCE DUE TO A COMMON FACTOR V GENE MUTATION IS A MAJOR RISK FACTOR FOR VENOUS THROMBOSISAnnual Review of Medicine, 1997
- The CUB DomainJournal of Molecular Biology, 1993
- Differing polarity of the constitutive and regulated secretory pathways for von Willebrand factor in endothelial cells.The Journal of cell biology, 1989
- Inducible secretion of large, biologically potent von Willebrand factor multimersCell, 1986
- Carbohydrate moiety of von Willebrand factor is not necessary for maintaining multimeric structure and ristocetin cofactor activity but protects from proteolytic degradation.Journal of Clinical Investigation, 1984